Generic Name and Formulations:
Sodium oxybate 500mg/mL; soln; contains sodium 91mg/mL.
Jazz Pharmaceuticals plc
Indications for XYREM:
Excessive daytime sleepiness and cataplexy associated with narcolepsy.
Take on empty stomach. Dilute each dose with 60mL of water. Initially 4.5g/night in two equally divided doses, at bedtime then again 2.5–4hrs later. May increase by 1.5g/night (0.75g/dose) at weekly intervals; usual range: 6–9g/night; max 9g/night. Allow 6hrs before becoming active after last dose. Consider concomitant CNS stimulant use (see full labeling). Hepatic impairment: reduce dose by ½, titrate and monitor closely. Concomitant divalproex sodium: reduce initial Xyrem dose by at least 20%; if already taking divalproex sodium, start Xyrem at lower dose; monitor, adjust accordingly.
Concomitant sedative hypnotics or alcohol. Succinic semialdehyde dehydrogenase deficiency.
CNS depression. Misuse and abuse.
Risk of CNS depression. Abuse potential (monitor). Respiratory dysfunction. History of depression or suicidal ideation (monitor). Consider sodium intake with heart failure, hypertension, renal insufficiency (see full labeling). Hepatic impairment. Drug abusers. Reevaluate every 3 months. Elderly. Labor & delivery. Pregnancy. Nursing mothers.
Antinarcoleptic (CNS depressant).
See Contraindications. CNS depression potentiated by concomitant other CNS depressants (eg, opioids, benzodiazepine, antidepressants, antipsychotics, general anesthetics, muscle relaxants). Potentiated by divalproex sodium.
Nausea, dizziness, vomiting, somnolence, enuresis, tremor; CNS and respiratory depression, sleepwalking, depressive symptoms, confusion, anxiety, other neuropsychiatric reactions.
Only available through the Xyrem REMS Program. For more information call (866) 997-3688.
Soln—180mL (w. oral dispensing syringe)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline